In the October 2016 issue of European Pharmaceutical Review, Andrew Butcher writes about the emergence of value-based pricing, where the price is determined as a function of measurable “value” brought by the product to relevant stakeholders. He discusses the challenges of measuring value in complex health systems and the importance of understanding the market and engaging a wide group of stakeholders well before a product launches. To read the article, click the link below.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...